Background: Bipolar disorder (BD) and schizophrenia (SC) have many similarities in clinical
manifestations. The acute phase of BD has psychotic symptoms, while SC also has …

Background The underlying disease mechanism of neuropsychiatric symptoms (NPS) in
dementia remains unclear. Cerebrospinal fluid (CSF) biomarkers for synaptic and axonal …

Ash1l potentially contributes to neurodevelopmental diseases. Although specific Ash1l
mutations are rare, they have led to informative studies in animal models that may bring …

The first-episode of psychosis is followed by a transient time-window of ca. 60 days during
which therapeutic interventions have a higher likelihood of being effective than interventions …

The management of schizophrenia endophenotypes, namely positive, negative, and
cognitive symptoms is still an open goal, justifying the search of novel therapeutic avenues …

Rationale Amphetamine enhances dopamine (DA) transmission and induces psychotic
states or exacerbates psychosis in at-risk individuals. Amphetamine sensitization of the DA …

Background: Schizophrenia is a highly heritable neurodevelopmental disorder. A genetic
variant of microRNA-137 (miR-137) has yielded significant genome-wide association with …

Schizophrenia is a common neuropsychiatric disorder with a lifetime risk of 1%.
Accumulation of common polygenic variations has been found to be an important risk factor …

This study aimed to explore the association between BDNF G196A gene rs6265
polymorphisms and the cognitive function and clinical symptoms of schizophrenia. Methods …

Current treatments for schizophrenia (SCZ) remain largely ineffective in one-third of patients.
Recent studies using stem cell therapy show a close relationship between stem cell …